Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. Rimassa L, Chan SL, Sangro B, Lau G, et al. J Hepatol 2025;83:899-908.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Rimassa L, Chan SL, Sangro B, Lau G, et al. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. J Hepatol 2025;83:899-908.
PMID: 40222621